Program
Horizon Europe – European Innovation Council (EIC) Accelerator
Duration
24 months (01/01/2025 - 31/12/2026)
Project funding
Funded by the European Union under Horizon Europe – European Innovation Council (EIC) Accelerator (Grant Agreement No. 101189252). EU contribution € 2 499 999,00.
Project goals
The objective of the OSTEOforUNION project is to develop and commercialise OSTEOGROW-C, an innovative biological drug for the treatment of bone fracture non-unions (FNU), one of the most significant unmet needs in orthopaedics. The project encompasses the implementation of a pivotal Phase III clinical trial (TRL 8), the scaling up and optimisation of the production process for the active ingredient rhBMP6, and comprehensive preparation for regulatory submission and marketing authorisation in both the European Union and the United States.
In parallel, the project focuses on establishing go-to-market strategies and strategic partnerships to ensure successful commercial deployment.
Project results
The expected outcome of the project is regulatory approval and the successful commercialisation of OSTEOGROW-C as a first-in-class biological therapy for bone fracture non-unions. Through advanced clinical validation, the project aims to demonstrate the safety and efficacy of the therapy, enabling market entry in the EU and US.
In doing so, OSTEOGROW-C is expected to contribute to reducing healthcare costs and complications associated with current treatment approaches, while strengthening the European Union’s position in biological drug development and regenerative medicine.
Funding Statement
The OSTEOforUNION project (Project number 101189252) is funded under the HORIZON-EIC-2024-ACCELERATOR-02 Call of the European Innovation Council (EIC) Accelerator programme. The action is supported by the European Innovation Council and SMEs Executive Agency (EISMEA) and managed through the EU Funding & Tenders Portal (eGrants). This project has received an EIC Accelerator Grant with a duration of 24 months.
Through this support, the European Union is enabling Genera Research to advance the development and future commercialization of OSTEOGROW-C, a novel biological drug solution for patients suffering from bone fracture nonunions.
Dora Adanić
Chief Operating Officer & Chief Financial Officer at Genera Research
As Chief Operating Officer & Chief Financial Officer at Genera Research, she oversees the company’s day-to-day operations, ensuring efficient management of personnel, resources, facilities, and logistics. With expertise in international business, business economics, and globalisation, she leads strategic planning and organisational development while coordinating cross-functional activities. Her role includes project management, stakeholder engagement, and oversight of marketing and operational workflows to support the company’s growth and long-term objectives.